10.28.2024 - POLA

Check out this week's QuadCast as we discuss if PCV is better than TMZ for oligodendroglioma, discuss results of the hypo-FLAME trial for prostate cancer, highlight adjuvant RT for high risk bladder cancer in the BART trial, and more.